Tag: PSMA-PET/CT
-
PSMA-PET/CT May Replace NaF-PET/CT in Advanced Prostate Cancer
PSMA-PET/CT Could Redefine Staging in High-Risk Prostate Cancer Imaging plays a pivotal role in determining treatment for men with newly diagnosed, high-risk prostate cancer. A recent Danish study suggests that replacing the conventional F-18 sodium fluoride (NaF) PET/CT with F-18 PSMA-PET/CT could significantly alter metastatic staging and, in turn, treatment decisions. The findings, published in…
-
Lu-177 PNT2002 Added to SBRT Delays Prostate Cancer Progression
New approach combines Lu-177 PNT2002 with SBRT In a pioneering study presented at the American Society for Radiation Oncology (ASTRO) meeting, researchers explored whether adding lutetium-177 (Lu-177) PNT2002 to stereotactic body radiation therapy (SBRT) could improve outcomes for men with oligometastatic, or limited, prostate cancer. The strategy targets occult micrometastases that often drive progression after…